{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:25:05Z","timestamp":1793330705622,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Dr. John A. Kerner Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite advances in cancer research, the majority of drug applications submitted to the U.S. Food and Drug Administration (FDA) are not approved. It is important to identify the concerns of the Oncologic Drugs Advisory Committee (ODAC) from rejected applications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All applications referred to the ODAC from 2001 to 2012 were reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 46 applications, 31 (67%) were for full and 15 (33%) were for supplemental approval, 34 (74%) were for solid and 12 (26%) were for hematologic tumors. In all, 22 (48%) were not approved. ODAC comments addressed missing or inadequate data (65%), excessive toxicity (55%), inappropriate study endpoints (45%), poor study design (40%), and insufficient sample size (30%). To define efficacy, 19 applications used response rates (RR) (median = 38%), and 19 applications used hazard ratios (HR) (median = 0.67). For all organ systems combined, the median cumulative grade 3 or 4 toxicity was 64%. Drugs with higher RR, lower HR, and lower toxicity were more likely to be approved versus other drugs (89% vs. 45%; p = .02). Over time (2001\u20132004, 2005\u20132008, 2009\u20132012), there was an increase in the following: number of applications submitted for review (from 11 to 12 to 23, respectively), number of approvals (from 6 to 6 to 12, respectively), and proportion of trials using progression-free survival as a primary endpoint (from 0% to 50% to 70%, respectively; p = .01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Of all applications, common ODAC concerns included inadequate data, excessive toxicity, and inappropriate study endpoints. Over time, there was an approximate doubling of FDA application submissions and approved oncology drugs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2013-0276","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T05:33:50Z","timestamp":1394084030000},"page":"299-304","source":"Crossref","is-referenced-by-count":4,"title":["Applications for Oncologic Drugs: A Descriptive Analysis of the Oncologic Drugs Advisory Committee Reviews"],"prefix":"10.1093","volume":"19","author":[{"given":"John K.","family":"Chan","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA;"},{"name":"Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen K.","family":"Kiet","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Creighton University School of Medicine, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole","family":"Young-Lin","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Blansit","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA;"},{"name":"Palo Alto Medical Foundation Research Institute, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Kapp","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoroenyi","family":"Amanam","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,3,5]]},"reference":[{"key":"2021122308461219200_B1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/djn267","article-title":"Speeding up the evaluation of new agents in cancer","volume":"100","author":"Parmar","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2021122308461219200_B2","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1001\/jama.2012.3424","article-title":"Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010","volume":"307","author":"Califf","year":"2012","journal-title":"JAMA"},{"key":"2021122308461219200_B3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drudis.2007.09.003","article-title":"Development trends for new cancer therapeutics and vaccines","volume":"13","author":"Reichert","year":"2008","journal-title":"Drug Discov Today"},{"key":"2021122308461219200_B4","first-page":"42S","article-title":"Principles of clinical trial design","volume":"20","author":"Nottage","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122308461219200_B5","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1200\/JCO.2003.01.204","article-title":"The phase III trial in the era of targeted therapy: Unraveling the \u201cgo or no go\u201d decision","volume":"21","author":"Roberts","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122308461219200_B6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: New estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J Health Econ"},{"key":"2021122308461219200_B7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1503\/cmaj.082040","article-title":"Drug development cost estimates hard to swallow","volume":"180","author":"Collier","year":"2009","journal-title":"CMAJ"},{"key":"2021122308461219200_B8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2021122308461219200_B9","volume-title":"Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Challenges and Opportunities Report","author":"U.S. Food and Drug Administration","year":"2004"},{"key":"2021122308461219200_B10","first-page":"612","article-title":"The FDA's new oncology office","volume":"3","author":"Pazdur","year":"2005","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021122308461219200_B11","article-title":"Factor associated with successful FDA approval after a positive phase III clinical trial using targeted anti cancer agents paper [oral presentation]","volume-title":"Presented at the proceeding of the Western Association of Gynecologic Oncology","author":"Chan","year":"2009"},{"key":"2021122308461219200_B12","first-page":"39","article-title":"What is the future of peer review? Why is there fraud in science? Is plagiarism out of control? Why do scientists do bad things? Is it all a case of: \u201call that is necessary for the triumph of evil is that good men do nothing\u201d?","volume":"3","author":"Triggle","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"2021122308461219200_B13","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMp078032","article-title":"The FDA and the case of Ketek","volume":"356","author":"Ross","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122308461219200_B14","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"Niraula","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308461219200_B15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrclinonc.2012.134","article-title":"Targeted therapies: The toxic reality of new drugs","volume":"9","author":"Kirk","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122308461219200_B16","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2007.14.8064","article-title":"Assessing the measure of a new drug: Is survival the only thing that matters?","volume":"26","author":"Sargent","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308461219200_B17","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2006.08.1935","article-title":"Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy","volume":"25","author":"Tang","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308461219200_B18","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","article-title":"Progression-free survival is a surrogate for survival in advanced colorectal cancer","volume":"25","author":"Buyse","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308461219200_B19","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: Meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308461219200_B20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1017\/S0266462308080495","article-title":"Progression-free survival as a surrogate endpoint in advanced breast cancer","volume":"24","author":"Miksad","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"2021122308461219200_B21","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/sj.bjc.6604759","article-title":"Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer","volume":"99","author":"Sherrill","year":"2008","journal-title":"Br J Cancer"},{"key":"2021122308461219200_B22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1067\/mcp.2001.115446","article-title":"Risks in new drug development: Approval success rates for investigational drugs","volume":"69","author":"Dimasi","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"2021122308461219200_B23","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.2011.35.2393","article-title":"Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs","volume":"29","author":"Amir","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2013-0276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0276","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/3\/299\/41861428\/oncolo_19_3_299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/3\/299\/41861428\/oncolo_19_3_299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T01:27:51Z","timestamp":1640309271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/3\/299\/6399247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,5]]},"published-print":{"date-parts":[[2014,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0276","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,3,1]]},"published":{"date-parts":[[2014,3,1]]}}}